UNSPSC 51373331: Naloxone/pentazocine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN101. This VA Drug Class (CN101) classifies this compound as belonging to the group OPIOID ANALGESICS.

UNSPSC 51373331 Naloxone/pentazocine, a Commodity code, covers pharmaceutical procurement for opioid antagonists and analgesics that state and local governments buy for emergency response, community health initiatives, and therapeutic pharmacy programs. Recent solicitations show Seminole County, Florida procuring naloxone units paired with drug deactivation systems for quarterly delivery to county health facilities, while the Texas Health and Human Services Commission is gathering vendor capability information through an RFI for direct-to-manufacturer prescription programs that may eventually include naloxone and related pharmaceuticals. The work encompasses both direct procurement of finished units for immediate deployment and preliminary market intelligence gathering to establish state-level pharmacy benefit contracting frameworks. Issuing bodies include county health departments and state HHS agencies; the Minnesota Multistate Cooperative Purchasing Alliance also uses the code tier within its broader generic pharmaceuticals RFP, suggesting regional cooperative purchasing vehicles are active in the space.

Activity appears concentrated in the South and Upper Midwest. Seminole County, Florida released IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023, requiring electronic bidding through the county's e-Procurement Portal and compliance with E-Verify and federal FEMA regulations if applicable. The Texas HHS Commission issued RFI HHS0017013 on April 3, 2026, to inform future RFP design for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program. Minnesota's cooperative RFP (S1070000015802), posted January 20, 2026, with proposals due March 26, 2026, establishes multi-award contracts for generic pharmaceuticals and OTC products distributed through authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson) effective July 1, 2026, with evaluations weighted 75 percent on price competitiveness and 10 percent on fixed pricing for the contract term. The code shows modest but steady activity across different procurement models — spot buys, RFI market research, and cooperative purchasing frameworks.